Cathie Wood's ARK Invest sold 250,062 shares of Tempus AI (TEM) on Tuesday. The sale from the ARK Innovation ETF (ARKK) totaled approximately $15.6 million. Tempus AI shares recently rallied after a Merck and Moderna clinical trial validated the company's acquisition of Personalis.
ARK Invest simultaneously purchased nearly 700,000 shares of Rocket Lab (RKLB) for approximately $44 million. The firm increased its position across multiple funds, including ARKK. This buying spree occurred while Rocket Lab stock faced pressure after NASA awarded a Mars mission contract to Blue Origin.
ARK also reduced its holdings in AMD, Twist Bioscience, and Shopify during recent sessions. These trades signal a strategic reallocation of capital toward the commercial space sector. The firm is taking profits from high-performing stocks to fund high-conviction investments despite recent market setbacks.